(Q36822111)

16 August 2017

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer (English)

1 reference

16 August 2017

1 reference

ChEBI release 2020-05-28

1

Razelle Kurzrock

1 reference

16 August 2017

18

Ravi Salgia

1 reference

16 August 2017

17

Mark J Ratain

1 reference

16 August 2017

8

Ezra E W Cohen

1 reference

16 August 2017

4

Arlene A Forastiere

1 reference

16 August 2017

Steven I Sherman

2

1 reference

16 August 2017

Douglas W Ball

3

1 reference

16 August 2017

Roger B Cohen

5

1 reference

16 August 2017

Ranee Mehra

6

1 reference

16 August 2017

David G Pfister

7

1 reference

16 August 2017

Linda Janisch

9

1 reference

16 August 2017

Forlisa Nauling

10

1 reference

16 August 2017

David S Hong

11

1 reference

16 August 2017

Chaan S Ng

12

1 reference

16 August 2017

Lei Ye

13

1 reference

16 August 2017

Robert F Gagel

14

1 reference

16 August 2017

John Frye

15

1 reference

16 August 2017

Thomas Müller

16

1 reference

16 August 2017

language of work or name

English

0 references

publication date

23 May 2011

1 reference

Journal of Clinical Oncology

16 August 2017

1 reference

16 August 2017

29

1 reference

16 August 2017

19

1 reference

16 August 2017

2660-2666

1 reference

Sorafenib: a clinical and pharmacologic review

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

MET receptor tyrosine kinase as a therapeutic anticancer target

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Modes of resistance to anti-angiogenic therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Motesanib diphosphate in progressive differentiated thyroid cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Phase II trial of sorafenib in advanced thyroid cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

New therapeutic approaches to treat medullary thyroid carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Advances in the treatment of gastrointestinal stromal tumours

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Recent progress in the management of advanced renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Structure and chemical inhibition of the RET tyrosine kinase domain

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646303

RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer

5 September 2018

1 reference

12 December 2020

Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid

1 reference

12 December 2020

Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation

1 reference

12 December 2020

Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma

1 reference

12 December 2020

Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2010.32.4145

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

21606412

1 reference